Kemantane in tuberculosis patients with intercurrent respiratory viral infection
Comparison in people · 1991
- What was studied
- 219 observed patients, 136 with and 83 without respiratory viral infection. Fourteen patients received Kemantane.
- Main finding
- In the 14 treated patients, the authors reported increased T-cell counts and lymphocyte blast formation. T-cell functional activity showed a favorable trend. Untreated patients’ immune measures were unchanged or tended to decline.
Reported findings and study design
Findings described in words
Pulmonary tuberculosis observational cohort (219). Of 136 with respiratory viral infection, 14 received Kemantane.
Population or model 219 observed patients, 136 with and 83 without respiratory viral infection. Fourteen patients received Kemantane.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| T-cell count and blast formation | Increases reported in the 14 treated patients. | Unchanged or declining measures reported in untreated patients. |
| T-cell functional activity | Upward trend reported in treated patients. |
The 19.1% aggravation figure concerned viral infection. It was not a between-arm estimate for Kemantane.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Treatment selection, dose, comparator denominator and the numerical immune effects require the full text.
- The 19.1% clinical aggravation figure describes the association with infection. A Kemantane effect on tuberculosis outcomes was not quantified.
Source details
Indexed English abstract of the original Russian journal report.
Sources checked
Citation
N. V. Kossii, I. S. Khomenko, V. Ia. Gergert. Kemantane in tuberculosis patients with intercurrent respiratory viral infection Probl Tuberk. 1991;(6):23–26.